相关实验视频

Updated: Jan 15, 2026

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI

Published on: July 21, 2023

提前诊断肝硬化:为什么非侵入性方法是未来?

Ram Prasad Chaulagain¹, Khuzin Dinislam², Yelona Shrestha³

¹Internal Medicine, Second Affiliated Hospital of Harbin Medical University, Harbin, CHN.

|January 14, 2026

概括

非侵入性方法 (NIMs) 正在彻底改变肝硬化诊断和监测. 这些安全和具有成本效益的工具,包括血清生物标志物和弹性图形,有望取代侵入性手术,改善患者的治疗结果.

科学领域:

肝病学肝病学是一种肝病学.
医学诊断医学诊断医学诊断
生物标志物研究生物标志物研究

背景情况:

肝硬化代表了慢性肝病的晚期阶段,构成了全球卫生挑战.
传统的诊断方法,如肝活检和HVPG测量有局限性,包括侵入性和患者的不适.

研究的目的:

审查诊断和监测肝硬化的非侵入性方法 (NIM) 的进展.
突出 NIM 替代传统侵入性技术的潜力.

主要方法:

审查目前的肝硬化非侵入性诊断和监测工具.
探索血清生物标志物 (例如,增强性肝纤维化试验,纤维化-4指数) 和弹性图像技术 (例如,VCTE,MRE).
讨论新兴技术,如人工智能驱动的放射学和多式联络方法.

主要成果:

非侵入性方法比传统方法提供安全性,成本效益和可重复性优势.
血清生物标志物和弹性图表在检测晚期纤维化时具有很高的准确性,并允许动态监测.
新兴技术有望进一步提高诊断准确性和早期检测.

结论:

越来越多的非侵入性方法被推作为一线工具,特别是在MASLD.
未来的发展重点是标准化,护理点设备和机器学习集成.
尼姆是精确肝病学的基础,旨在取代侵入性技术并提高患者护理.

关键词:

人工智能的人工智能是人工智能.弹性学弹性学弹性学肝硬化是肝硬化的一种疾病.多式联络诊断系统多式联络诊断系统非侵入性诊断是一种非侵入性诊断.血清中的生物标志物

更多相关视频

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

相关概念视频

Ultrasound II: Endoscopic Ultrasound and FibroScan

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...